declares having received consulting honoraria from Amgen, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk and Bayer, and research grants from British Heart Foundation, MRC (UK), NIHR, PHE, MSD, Pfizer, Aegerion, Colgate and Roche
By activating both GLP-1 and GIP receptors simultaneously, tirzepatide reduces appetite, enhances insulin sensitivity, slows digestion for prolonged fullness, and may even increase calorie burning
The question is what happens when all of them land together, and thats a question the FDA hasnt fully answered yet
The largest increases in first-time CVD diagnosis following first-time GLP-1 RA prescription were seen in the group of people having overweight or BMIs between 27 to 30 (34.5% increase from 2020 to 2024)
A meal heavy in fat or fiber takes 4 to 6 hours to digest even without tirzepatide, and once the drug begins slowing gastric emptying after injection, that meal could sit for 8 to 10 hours